Nvidia (NASDAQ:NVDA) shocked the market last month by disclosing it had dumped all of its shares in artificial intelligence voice recognition expert SoundHound AI ( NASDAQ:SOUN ), Serve Robotics (NASDAQ:SERV), and Nano X Imaging (NASDAQ:NNOX).
Nano-X Imaging is my speculative play for disruptive innovation in the biotech sector. With the S&P 500 at historical highs, lagging sectors like healthcare seem relatively attractive. The biotech sector's large market size and potential make it an intriguing investment opportunity. The AI push in health sector is a long-term tailwind. NNOX is positioned well in offering real value from the AI system.
Here is how Nano-X Imaging Ltd. (NNOX) and VerifyMe, Inc. (VRME) have performed compared to their sector so far this year.
Shares of medical imaging company Nano-X Imaging (NNOX 3.02%) -- commonly referred to as Nanox -- went up on Thursday after some pretty substantial news broke regarding regulatory clearance. At 10:50 a.m.
Nano-X Imaging Ltd. (NASDAQ:NNOX ) Q3 2024 Earnings Conference Call November 21, 2024 8:30 AM ET Company Participants Mike Cavanaugh - IR Erez Meltzer - CEO Ran Daniel - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Jeffrey Cohen - Ladenburg Scott Henry - Alliance Global Operator Ladies and gentlemen, thank you for standing by.
PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2024, before market open on Thursday, November 21, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Company management will participate in an investor conference in the month of September 2024:
HealthCCSng V2.0 i ntroduces additional ‘ zero calcium ' categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC d etection c ategory output
Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand Nanox.ARC indications to include general use, including chest Nanox.AI Receives FDA 510K Clearance for HealthCCSng V 2.0, upgraded version of its AI Cardiac Solution Management to host conference call and webcast Tuesday, August 20, 2024 at 8:30 AM ET PETAH TIKVA, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2024 and provided a business update. Recent Highlights: Generated $2.7 million in revenue in the second quarter of 2024, compared to $2.6 million in the second quarter of 2023.
Nano-X Imaging is especially popular with analysts. Recursion Pharmaceuticals plans to report results from seven clinical studies over the next 18 months.